A clinical prediction rule for nerve-function impairment in leprosy patients
Croft, Richard P., Nicholls, Peter G., Steyerberger, Ewout W., Richardus, Jan H. and Smith, W. Cairns S. (2000) A clinical prediction rule for nerve-function impairment in leprosy patients. The Lancet, 355, (9215), 1603-1606. (doi:10.1016/S0140-6736(00)02216-9). (PMID:10821364).
Nerve-function impairment (NFI) commonly occurs during or after chemotherapy in leprosy and is the key pathological process leading to disability and handicap. We describe the development of a simple clinical prediction rule for estimating the risk of NFI occurrence.
New leprosy cases who presented to a centre in Bangladesh were recruited and followed up for 2 years in a field setting. We used multivariable regression analysis by Cox's proportional hazards model to identify predictive variables for NFI. Discriminative ability was measured by a concordance statistic. Internal validity was assessed with bootstrap resampling techniques.
2510 patients were followed up for 2 years, 166 developed NFI. A simple model was developed with leprosy group (either paucibacillary leprosy [PB] or multibacillary leprosy [MB]) and the presence of any nerve-function loss at registration as predictive variables. Patients with PB leprosy and no nerve-function loss had a 1·3% (95% Cl 0·8–1·8%) risk of developing NFI within 2 years of registration; patients with PB leprosy and nerve-function loss, or patients with MB leprosy and no nerve-function loss had a 16·0% (12–20%) risk; and patients with MB leprosy with nerve-function loss had a 65% (56–73%) risk.
Our prediction rule can be used to plan surveillance of new leprosy patients. Patients at low risk of NFI may need no follow-up beyond their course of chemotherapy (6 months); patients with intermediate risk need a minimum of 1 year of surveillance; and patients with high risk should have at least 2 years of surveillance for new NFI. Current recommendations for surveillance of patients with leprosy (for the duration of chemotherapy only) exclude an important group of patients who are at risk of developing NFI after completion of treatment.
|Subjects:||R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
R Medicine > RM Therapeutics. Pharmacology
|Divisions:||University Structure - Pre August 2011 > School of Health Sciences
|Date Deposited:||04 Nov 2010 15:35|
|Last Modified:||08 Jun 2012 12:59|
|Contributors:||Croft, Richard P. (Author)
Nicholls, Peter G. (Author)
Steyerberger, Ewout W. (Author)
Richardus, Jan H. (Author)
Smith, W. Cairns S. (Author)
|Date:||6 May 2000|
|RDF:||RDF+N-Triples, RDF+N3, RDF+XML, Browse.|
Actions (login required)